Lifestyle or pharmacotherapy in cardio-metabolic disease prevention [0.03%]
生活方式与药物治疗在心血管代谢性疾病预防中的作用
Borenyi S Seidu,Hanad Osman,Samuel Seidu
Borenyi S Seidu
Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease ...
Identification of biomarkers, pathways, and potential therapeutic targets for heart failure using next-generation sequencing data and bioinformatics analysis [0.03%]
基于下一代测序数据和生物信息学分析的心力衰竭生物标志物、通路及潜在治疗靶点鉴定
Prashanth Ganekal,Basavaraj Vastrad,Chanabasayya Vastrad et al.
Prashanth Ganekal et al.
Background: Heart failure (HF) is the most common cardiovascular diseases and the leading cause of cardiovascular diseases related deaths. Increasing molecular targets have been discovered for HF prognosis and therapy. Ho...
Prevalence and factors associated with drug therapy problems among hypertensive patients at hypertension clinic of Mbarara Regional Referral Hospital, Uganda: a |cross-sectional study [0.03%]
乌干达姆巴腊地区转诊医院高血压门诊患者的药物治疗问题及相关因素的横断面研究
Merab Babirye,Tadele Mekuriya Yadesa,Robert Tamukong et al.
Merab Babirye et al.
Background: Despite the use of safe and effective conventional drugs, drug therapy problems (DTPs) pose a threat to the successful management of hypertension. DTPs are of a great concern in health care because of their se...
Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study [0.03%]
肾上腺素治疗经皮冠状动脉介入术后无复流现象的疗效和安全性：系统评价研究报告
Elmira Jafari Afshar,Parham Samimisedeh,Amirhossein Tayebi et al.
Elmira Jafari Afshar et al.
Background: Currently, no pharmacological or device-based intervention has been fully proven to reverse the no-reflow phenomenon. Objectives: ...
Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020) [0.03%]
COVID-19大流行对心血管疾病药物使用的影响：COVID-19大流行期间（2019年1月至2020年10月）英格兰的用药时间序列分析
Ravina Barrett,James Hodgkinson
Ravina Barrett
Background: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some...
The GENICA project - a prospective cohort of heart failure patients with a comprehensive ambulatory approach aiming better outcomes: study protocol [0.03%]
GENICA项目 - 一个采用全面的门诊方案来改善预后的前瞻性心力衰竭队列研究：研究方案
Carla Sofia de Almeida Martins,João Abranches Figueiredo Simões de Carvalho,Manuel Vaz da Silva et al.
Carla Sofia de Almeida Martins et al.
Introduction: Heart failure (HF) is a syndrome increasing worldwide, and literature shows that the hospitalizations are associated with greater mortality rates. A patient-centered method combined with optimized medical tr...
Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters [0.03%]
SLCO1B1基因单核苷酸多态性与辛伐他汀多种效应的关联：通过血流介导的扩张内皮功能参数测量得的结果
Andrianto,Mia Puspitasari,Meity Ardiana et al.
Andrianto et al.
Background: Atherosclerosis is a condition in which the medium to large arteries become inflamed over time. The cornerstone to the atherosclerosis process is endothelial dysfunction. Simvastatin is a cholesterol-lowering ...
Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy [0.03%]
巴反射激活治疗后射血分数降低的心力衰竭患者运动时的心肺功能
Pia I Nottebohm,Daniel Dumitrescu,Stefanie Hamacher et al.
Pia I Nottebohm et al.
Purpose: Baroreflex activation therapy has favorable effects in heart failure patients. We report the results of a single-center study of baroreflex activation therapy in heart failure with reduced ejection fraction inclu...
Interventional cardiac magnetic resonance imaging: current applications, technology readiness level, and future perspectives [0.03%]
心脏介入磁共振成像：当前应用、技术成熟度和未来展望
Sophie C Rier,Suzan Vreemann,Wouter H Nijhof et al.
Sophie C Rier et al.
Background: Cardiac magnetic resonance (CMR) provides excellent temporal and spatial resolution, tissue characterization, and flow measurements. This enables major advantages when guiding cardiac invasive procedures compa...
Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy [0.03%]
远端心室起搏在中间腔室梗阻性肥厚型心肌病中的治疗益处
James W Malcolmson,Rebecca K Hughes,Abhishek Joshi et al.
James W Malcolmson et al.
Introduction: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We...